Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.

The Lancet Oncology
Neal D ShoreAxel Heidenreich

Abstract

Enzalutamide is an oral androgen-receptor inhibitor that has been shown to improve survival in two placebo-controlled phase 3 trials, and is approved for patients with metastatic castration-resistant prostate cancer. The objective of the TERRAIN study was to compare the efficacy and safety of enzalutamide with bicalutamide in patients with metastatic castration-resistant prostate cancer. TERRAIN was a double-blind, randomised phase 2 study, that recruited asymptomatic or minimally symptomatic men with prostate cancer progression on androgen-deprivation therapy (ADT) from academic, community, and private health-care provision sites across North America and Europe. Eligible patients were randomly assigned (1:1) via an interactive voice response system to receive enzalutamide 160 mg/day or bicalutamide 50 mg/day, both taken orally, in addition to ADT, until disease progression. Patients were stratified by a permutated block method (block size of four), by whether bilateral orchiectomy or receipt of luteinising hormone-releasing hormone agonist or antagonist therapy started before or after the diagnosis of metastases, and by study site. Participants, investigators, and those assessing outcomes were masked to group assignment. The p...Continue Reading

References

Nov 22, 2001·Journal of the National Cancer Institute·M E GrossmannD J Tindall
Jan 2, 2004·Nature Medicine·Charlie D ChenCharles L Sawyers
Oct 11, 2005·Urologia Internationalis·Ramaswamy ManikandanGerald N Collins
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jul 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen E Knudsen, Howard I Scher
Apr 20, 2010·Lancet·Howard I ScherUNKNOWN Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium
Mar 6, 2012·Expert Review of Endocrinology & Metabolism·Karen E Knudsen, William Kevin Kelly
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Dec 11, 2013·European Urology·Axel HeidenreichUNKNOWN European Association of Urology
Jun 7, 2014·BJU International·Alejo Rodriguez-VidaSimon Chowdhury
Sep 10, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ethan BaschKatherine S Virgo
Oct 30, 2014·The New England Journal of Medicine·Tomasz M Beer, Bertrand Tombal

❮ Previous
Next ❯

Citations

May 11, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giandomenico RovielloDaniele Generali
May 24, 2016·Expert Review of Anticancer Therapy·Chiara CiccareseFrancesco Massari
Sep 18, 2016·Critical Reviews in Oncology/hematology·Giulia Baciarello, Cora N Sternberg
Aug 30, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karim Fizazi
Nov 7, 2016·Current Problems in Cancer·Ayca Gucalp, Tiffany A Traina
Nov 9, 2016·Current Treatment Options in Oncology·Catherine E Handy, Emmanuel S Antonarakis
Nov 16, 2016·Indian Journal of Urology : IJU : Journal of the Urological Society of India·K C Balaji
Nov 2, 2016·Cancer·Edoardo Francini, Mary-Ellen Taplin
Mar 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark N Stein, Thomas L Jang
Mar 7, 2017·Journal of the American Geriatrics Society·Kerri M Winters-StoneTomasz M Beer
Mar 9, 2017·Journal of Medicinal Chemistry·Claudia FerroniGreta Varchi
Apr 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine S VirgoEric A Singer
Jan 27, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tiffany A TrainaJavier Cortes
Mar 30, 2018·Expert Opinion on Emerging Drugs·Eric S Christenson, Emmanuel S Antonarakis
Oct 4, 2017·Endocrine-related Cancer·Gianmarco LeoneMassimo Di Maio
Jun 28, 2018·The New England Journal of Medicine·Maha HussainCora N Sternberg
Aug 18, 2018·Molecular Oncology·Margaret M CenteneraWayne D Tilley
Nov 22, 2018·Expert Opinion on Pharmacotherapy·Athanasios E Dellis, Athanasios G Papatsoris
May 8, 2018·The Journal of Urology·E David CrawfordFernand Labrie
Feb 3, 2016·Nature Reviews. Urology·Peter Sidaway
Oct 19, 2017·Nature Reviews. Clinical Oncology·Min Yuen TeoHoward I Scher
May 16, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·James L MohlerDeborah A Freedman-Cass
Jul 4, 2019·The New England Journal of Medicine·Laurence Klotz
Jul 23, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J ArmstrongArnulf Stenzl
Sep 27, 2019·Cancer Investigation·Xiaolei Zhu, Shenhong Wu
Aug 3, 2017·Annals of Surgical Oncology·Ayca Gucalp, Tiffany A Traina
Mar 16, 2016·Current Opinion in Endocrinology, Diabetes, and Obesity·Benjamin A Teply, Emmanuel S Antonarakis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.